MARKET

RNAC

RNAC

Cartesian
NASDAQ
16.61
-0.87
-4.98%
After Hours: 16.61 0 0.00% 16:05 03/13 EDT
OPEN
17.13
PREV CLOSE
17.48
HIGH
17.42
LOW
16.25
VOLUME
102.88K
TURNOVER
--
52 WEEK HIGH
41.87
52 WEEK LOW
11.67
MARKET CAP
427.30M
P/E (TTM)
-0.4396
1D
5D
1M
3M
1Y
5Y
1D
Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham
Dow Jones · 5h ago
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $41 Price Target
Benzinga · 5h ago
Based on the provided financial report, the title of the article is: "FORM 10-K: ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Press release · 12h ago
Cartesian Therapeutics GAAP EPS of -$4.49 beats by $1.38, revenue of $38.91M misses by $0.83M
Seeking Alpha · 12h ago
CARTESIAN THERAPEUTICS : PHASE 2 TRIAL OF DESCARTES-08 IN SYSTEMIC LUPUS ERYTHEMATOSUS ONGOING WITH EXPECTED DATA READOUT IN 2H25
Reuters · 12h ago
CARTESIAN THERAPEUTICS : EXPECTS TO INITIATE PHASE 2 PEDIATRIC BASKET TRIAL OF DECARTES-08 IN SELECT AUTOIMMUNE INDICATIONS IN 2H25
Reuters · 12h ago
*Cartesian Therapeutics FY24 Loss $77.4M >RNAC
Dow Jones · 12h ago
Press Release: Cartesian Therapeutics Reports -2-
Dow Jones · 12h ago
More
About RNAC
More
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Recently
Symbol
Price
%Change

Webull offers Cartesian Therapeutics Inc stock information, including NASDAQ: RNAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAC stock methods without spending real money on the virtual paper trading platform.